{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:24:44Z","timestamp":1784366684416,"version":"3.55.0"},"reference-count":31,"publisher":"Sociedad Espanola de Patologia Digestiva (SEPD)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Enferm Dig"],"published-print":{"date-parts":[[2018]]},"DOI":"10.17235\/reed.2018.5533\/2018","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T05:37:14Z","timestamp":1525757834000},"source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA"],"prefix":"10.17235","volume":"110","author":[{"given":"Weijia","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6910","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1.Rudic, JS, G Poropat, MN Krstic, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012; 12: CD000551.","DOI":"10.1002\/14651858.CD000551.pub3"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"1.\tRudic JS, Poropat G, Krstic MN, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012; 12: CD000551.","DOI":"10.1002\/14651858.CD000551.pub3"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"2.\tPares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology2006;130:715-20.","DOI":"10.1053\/j.gastro.2005.12.029"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"3.\tCorpechot C, Abenavoli L, Rabahi N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology2008;48:871-7.","DOI":"10.1002\/hep.22428"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"4.\tKuiper EM, Hansen BE, de Vries RA, et al.Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology2009;136:1281-7.","DOI":"10.1053\/j.gastro.2009.01.003"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"5.\tZhang, LN, Shi TY, Shi XH, et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology2013;58:264-72.","DOI":"10.1002\/hep.26322"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"6.\tOhira H, Sato Y, Ueno T, et al.Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol2002;97:2147-9.","DOI":"10.1111\/j.1572-0241.2002.05944.x"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"7.\tDohmen K, Mizuta T, Nakamuta M, et al.Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol2004;10:894-8.","DOI":"10.3748\/wjg.v10.i6.894"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"8.\tWalker LJ, Newton J, Jones DE, et al.Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology2009;49:337-8.","DOI":"10.1002\/hep.22670"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"9.\tLiberopoulos EN, Florentin M, Elisaf MS, et al.Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J2010;4:120-6.","DOI":"10.2174\/1874192401004010120"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"10.\tLevy C, Peter JA, Nelson DR, et al.Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment PharmacolTher2011;33:235-42.","DOI":"10.1111\/j.1365-2036.2010.04512.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"11.\tHan XF,. Wang QX, Liu Y, et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis2012;13:219-24.","DOI":"10.1111\/j.1751-2980.2012.00574.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"12.\tLindor KD, Gershwin ME, Poupon R, et al.Primary biliary cirrhosis. Hepatology2009;50: 291-308.","DOI":"10.1002\/hep.22906"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"14.   Lens S,  Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int2014;34:197-203.","DOI":"10.1111\/liv.12290"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"15.\tSuk KT, Baik SK, Yoon JH, et al.Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol2012;18:1-21.","DOI":"10.3350\/kjhep.2012.18.1.1"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"16.\tPannu N, Nadim MK.An overview of drug-induced acute kidney injury.Crit Care Med2008;36(4 Suppl): S216-23.","DOI":"10.1097\/CCM.0b013e318168e375"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"17.\tSchetz M, Dasta J, Goldstein S, et al.Drug-induced acute kidney injury.CurrOpinCrit Care2005;11:555-65.","DOI":"10.1097\/01.ccx.0000184300.68383.95"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"18.\tMehta RL, Kellum JA, Shah SV, et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.CritCare 2007;11:R31.","DOI":"10.1186\/cc5713"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"19.\tLevey AS, Stevens LA, Schmid CH, et al.A new equation to estimate glomerular filtration rate. Ann Intern Med2009;150: 604-12.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"20.\tLevey AS, Coresh J, Greene T, et al.Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.ClinChem2007;53:766-72.","DOI":"10.1373\/clinchem.2006.077180"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"22.\tHegade VS, Khanna A, Walker LJ, et al.Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. Dig Dis Sci2016; 61:3037-44.","DOI":"10.1007\/s10620-016-4250-y"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"23.\tCheung AC, Lapointe-Shaw L, Kowgier M, et al.Combinedursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment PharmacolTher2016;43:283-93.","DOI":"10.1111\/apt.13465"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"24.\tYang F, Yang Y, Wang Q, et al., The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment PharmacolTher2017;45: 733-43.","DOI":"10.1111\/apt.13927"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"25.\tAttridge RL, Linn WD, Ryan L, et al. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J ClinLipidol2012;6:19-26.","DOI":"10.1016\/j.jacl.2011.08.008"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"26.\tAnsquer JC, Dalton RN, Causse E, et al.Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis2008;51:904-13.","DOI":"10.1053\/j.ajkd.2008.01.014"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"27.\tZhao YY, Weir MA, Manno M, et al.New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med2012;156:560-9.","DOI":"10.7326\/0003-4819-156-8-201204170-00401"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"28.\tAttridge RL, Frei CR, Ryan L, et al.Fenofibrate-associated nephrotoxicity: a review of current evidence. Am J Health Syst Pharm2013;70:1219-25.","DOI":"10.2146\/ajhp120131"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"29.\tBonds DE, Craven TE, Buse J, et al.Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.Diabetologia2012;55:1641-50.","DOI":"10.1007\/s00125-012-2524-2"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"30.\tMychaleckyj JC, Craven T, Nayak U, et al.Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35:1008-14.","DOI":"10.2337\/dc11-1811"}],"container-title":["Revista Espa\u00f1ola de Enfermedades Digestivas"],"original-title":[],"deposited":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T05:38:31Z","timestamp":1525757911000},"score":1,"resource":{"primary":{"URL":"https:\/\/online.reed.es\/fichaArticulo.aspx?iarf=685766747235-414278194167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":31,"URL":"https:\/\/doi.org\/10.17235\/reed.2018.5533\/2018","relation":{},"ISSN":["1130-0108"],"issn-type":[{"value":"1130-0108","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}